Alaunos Therapeutics Inc
TCRT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.71M
Close$
$0.53
69.9% downside
Current Fair Value
69.9% downsideOvervalued by 69.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.71 Million |
|---|---|
| Enterprise Value | $5.58 Million |
| Earnings per Share | $-2.2 |
| Beta | -0.97 |
| Outstanding Shares | 2,431,695 |
Return
| Return on Equity | -615.03% |
|---|---|
| Return on Assets | -264.51% |
| Return on Invested Capital | -625.31% |
Valuation & Multiples
| P/E Ratio | -1 |
|---|---|
| PEG | 10.62 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1861.3 |
| Enterprise Value to EBIT | -1.37 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-15.75
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 3.71% |
|---|---|
| Total Invested | $101▼ 99.95% |
| Investors Holding | 4▼ 26.00% |
About Alaunos Therapeutics Inc
105 employees
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled int...